---
figid: PMC4801458__koni-05-02-1078966-g001
figlink: /pmc/articles/PMC4801458/figure/f0001/
number: F1
caption: 'BRAF (V600E) mediates immune suppression and evasion through multiple mechanisms
  in melanoma. The acquisition of a somatic BRAF(V600E) mutation is an early event
  during melanomagenesis and leads to constitutive activation of the MAPK signaling
  pathway. This promotes: (1) Increased internalization and endosomal sequestration
  of HLA class I molecules, directly reducing surface expression and tumor-cell recognition
  by cytotoxic T cells; (2) Upregulation of chemokines CXCL8, CCL2, and IL-1, which
  can attract myeloid cell subsets including monocytes and tumor-associated macrophages,
  as well as tumor-associated fibroblasts (TAFs) into the tumor microenvironment (TME);
  (3) Transcription and expression of IL-1α/β, IL-6, and VEGF, which can condition
  the cells of the TME. IL-1α/β production by tumor cells can promote T-cell suppression
  by inducing the expression of programmed death (PD)-1 ligands PD-L1 and PD-L2 on
  TAFs, in addition to increasing COX-2 transcription and PGE2 upregulation. VEGF
  can inhibit myeloid cell maturation, in addition to directly promoting the functional
  inhibition of T cells through VEGFR2.'
pmcid: PMC4801458
papertitle: 'Trouble at the core: BRAF(V600E) drives multiple modes of T-cell suppression
  in melanoma.'
reftext: Sherille D. Bradley, et al. Oncoimmunology. 2016 Feb;5(2):e1078966.
pmc_ranked_result_index: '155652'
pathway_score: 0.7523724
filename: koni-05-02-1078966-g001.jpg
figtitle: BRAF (V600E) mediates immune suppression and evasion through multiple mechanisms
  in melanoma
year: '2016'
organisms: Homo sapiens
ndex: 9e1a3c12-dea9-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4801458__koni-05-02-1078966-g001.html
  '@type': Dataset
  description: 'BRAF (V600E) mediates immune suppression and evasion through multiple
    mechanisms in melanoma. The acquisition of a somatic BRAF(V600E) mutation is an
    early event during melanomagenesis and leads to constitutive activation of the
    MAPK signaling pathway. This promotes: (1) Increased internalization and endosomal
    sequestration of HLA class I molecules, directly reducing surface expression and
    tumor-cell recognition by cytotoxic T cells; (2) Upregulation of chemokines CXCL8,
    CCL2, and IL-1, which can attract myeloid cell subsets including monocytes and
    tumor-associated macrophages, as well as tumor-associated fibroblasts (TAFs) into
    the tumor microenvironment (TME); (3) Transcription and expression of IL-1α/β,
    IL-6, and VEGF, which can condition the cells of the TME. IL-1α/β production by
    tumor cells can promote T-cell suppression by inducing the expression of programmed
    death (PD)-1 ligands PD-L1 and PD-L2 on TAFs, in addition to increasing COX-2
    transcription and PGE2 upregulation. VEGF can inhibit myeloid cell maturation,
    in addition to directly promoting the functional inhibition of T cells through
    VEGFR2.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PDCD1LG2
  - CXCL8
  - CD274
  - CXCL11
  - CXCL14
  - CXCL13
  - CXCL10
  - KDR
  - CXCL3
  - IL6
  - PDCD1
  - CXCL9
  - PF4
  - PPBP
  - CXCL5
  - CXCL12
  - CCL2
  - CD8A
  - CD8B
  - CXCL1
  - CXCL2
  - IL1B
  - TRB
  - CXCL6
  - BRAF
  - TRA
  - PGF
  - IL24
  - VEGFD
  - TRG
  - TRD
  - IL1A
  - VEGFC
  - VEGFA
  - VEGFB
  - PGE
genes:
- word: PD-L2
  symbol: PD-L2
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1LG2
  entrez: '80380'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL11
  entrez: '6373'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL14
  entrez: '9547'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL13
  entrez: '10563'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL10
  entrez: '3627'
- word: VEGFR2
  symbol: VEGFR2
  source: hgnc_alias_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL3
  entrez: '2921'
- word: IL-6
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL9
  entrez: '4283'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PF4
  entrez: '5196'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: PPBP
  entrez: '5473'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL5
  entrez: '6374'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
- word: CCL2
  symbol: CCL2
  source: hgnc_symbol
  hgnc_symbol: CCL2
  entrez: '6347'
- word: CD8+
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: CD8+
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL1
  entrez: '2919'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL2
  entrez: '2920'
- word: IL-1a/B
  symbol: IL-1B
  source: hgnc_alias_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRB
  entrez: '6957'
- word: Chemokine
  symbol: Chemokine
  source: bioentities_symbol
  hgnc_symbol: CXCL6
  entrez: '6372'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRA
  entrez: '6955'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: CXCL8
  symbol: CXCL8
  source: hgnc_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: IL-10B
  symbol: IL10B
  source: hgnc_alias_symbol
  hgnc_symbol: IL24
  entrez: '11009'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRG
  entrez: '6965'
- word: TCR
  symbol: TCR
  source: bioentities_symbol
  hgnc_symbol: TRD
  entrez: '6964'
- word: IL-1a/B
  symbol: IL-1A
  source: hgnc_alias_symbol
  hgnc_symbol: IL1A
  entrez: '3552'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
chemicals:
- word: PGE
  source: MESH
  identifier: D011458
diseases: []
figid_alias: PMC4801458__F1
redirect_from: /figures/PMC4801458__F1
figtype: Figure
---
